Tag: Biomarkers
-
SerpinB3: A Cancer Biomarker That Also Shapes Wound Healing
What is SerpinB3 and why it matters SerpinB3 is a protein that can rise in the bloodstream when the body’s tissues are under stress or damage. While most people associate elevated biomarkers with cancer, SerpinB3 plays a broader role in the body’s protective responses. Researchers are increasingly recognizing that SerpinB3 not only signals potential malignancies…
-
Inflammation Drives Early Lung Cancer: MD Anderson Maps
New Insights into the Onset of Lung Cancer Researchers at The University of Texas MD Anderson Cancer Center have unveiled a landmark approach to understanding how lung cancer begins. By creating high-resolution cellular and molecular maps of lung tissue before and during cancer development, the team shows that chronic inflammation may be a primary driver…
-
Heart checks could flag dementia risk 25 years early, study suggests
New findings link heart health to future dementia risk A growing body of research indicates that indicators normally associated with heart health in midlife may also reveal future cognitive risks. In a recent study, scientists found that higher levels of a protein called troponin in the blood during midlife were associated with an increased likelihood…
-
Early Heart Checks Could Signal Dementia Risk 25 Years Early
New evidence links heart biomarkers to future dementia risk A new study suggests that a simple blood test in midlife could forecast a person’s risk of developing dementia up to 25 years later. The key finding centers on troponin, a protein traditionally used to diagnose heart injury. In this study, higher midlife troponin levels were…
-
Why Some Breast Cancers Resist Antibody Drug Conjugates (ADCs)
Unraveling Resistance to Antibody Drug Conjugates in Breast Cancer Antibody drug conjugates (ADCs) represent a promising class of targeted cancer therapies that couple a tumor-homing antibody with a potent cytotoxic payload. In breast cancer, this approach aims to deliver chemotherapy directly to malignant cells while sparing most healthy tissue. Yet, not all patients respond, and…
-
New Insights into Why Some Breast Cancers Resist Antibody-Drug Conjugates (ADCs) Therapy
Understanding ADCs and Why They Matter in Breast Cancer Antibody‑drug conjugates (ADCs) are a cutting‑edge class of cancer therapies designed to target malignant cells with precision. By pairing a cancer‑specific antibody with a potent cytotoxic drug, ADCs aim to destroy tumor cells while limiting damage to healthy tissue. In breast cancer, ADCs have shown promise,…
-
Inflammasome Proteins Offer New Path in Pediatric Traumatic Brain Injury Assessment
Breakthrough in Pediatric TBI Evaluation: Biomarkers ASC and caspase-1 A new study published in Nature Pediatric Research highlights a promising biomarker-based approach to assessing pediatric traumatic brain injury (TBI). Led by Dr. Jennifer Muñoz Pareja, the research examines serum inflammasome proteins ASC and caspase-1, revealing that their levels rise significantly in children with TBI and…
-
Inflammasome Proteins Improve Pediatric Traumatic Brain Injury Assessment
New Biomarkers Offer Fresh Insight into Pediatric TBI Pediatric traumatic brain injury (TBI) remains a major medical challenge with potential long‑term cognitive, behavioral, and motor consequences. A groundbreaking study published in Nature Pediatric Research introduces a serum biomarker approach that could transform how clinicians evaluate injury severity and guide treatment in children. Led by Dr.…
-
Genetic Resilience: A Distinct COPD Subtype In Smokers With High Genetic Risk
Understanding Genetic Resilience in COPD COPD shows substantial variability in how it develops among people who smoke. While a genetic risk score helps predict who is more likely to develop COPD, many individuals with high genetic risk do not actually develop the disease. Recent research introduces the concept of genetic resilience to COPD—a clinically meaningful…
-
Longevity Breakthrough: Oxytocin + A5i Extend Lifespan
Overview New research suggests a dual-drug approach could unlock longer life in aging organisms. In a study published in Ageing-US, scientists explored a combination therapy using oxytocin and OT+A5i, a compound that blocks a key growth-regulating pathway. The aim: slow aging processes and improve healthspan by addressing two biological pathways that change with age. The…